



PATENT

Case Docket No. ABGENIX.030C1
Date: October 8, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER

**COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing thirty-seven (37) references.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Michael L. Fuller
Registration No. 36,516
Attorney of Record
Customer No. 20,995
(619) 235-8550



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Bar-Eli et al.) Group Art Unit: Not assigned
)
App. No.	:	10/660,357)
)
Filed	:	September 10, 2003)
)
For	:	USE OF ANTIBODIES)
		AGAINST THE MUC18)
		ANTIGEN)
)
Examiner	:	Not assigned)

INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing thirty-seven (37) references that were previously disclosed to the Patent and Trademark Office in the prosecution of U.S. patent application No. 10/330,580, filed December 26, 2002, which is the parent of this application, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 8, 2003

By: _____

Michael L. Fuller
Registration No. 36,516
Attorney of Record
Customer No. 20,995
(619) 235-8550



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ABGENIX.030C1	APPLICATION NO. 10/660,357
	APPLICANT Bar-Eli et al.	
	FILING DATE September 10, 2003	GROUP Not assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1.		4,735,210	04/05/98	Goldenberg	128	654	
2.		5,101,827	04/07/92	Goldenberg	128	653.4	
3.		5,102,990	04/07/92	Rhodes	530	391.5	
4.		5,648,471	07/15/97	Buttram et al.	424	1.49	
5.		5,697,901	12/16/97	Eriksson	604	46	


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

6.	Anfosso et al., "Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125 ^{FAK} ," <i>J. Bio. Chem.</i> , 273(41):26852-26856 (1998)
7.	Bani et al., "Multiple Features of Advanced Melanoma Recapitulated in Tumorigenic Variants of Early Stage (Radial Growth Phase) Human Melanoma Cell Lines: Evidence for a Dominant Phenotype," <i>Cancer Res.</i> , 56:3075-3086 (1996)
8.	Bar-Eli, M., "Role of AP-2 in tumor growth and metastasis of human melanoma," <i>Cancer and Metastasis Reviews</i> , 18:377-385 (1999)
9.	Frankel et al., "Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A Review," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 15(5):459-476 (2000)
10.	Hedrick et al., "The DCC gene product in cellular differentiation and colorectal tumorigenesis," <i>Genes & Development</i> , 8:1174-83 (1994)
11.	Holzmann et al. "Tumor Progression in Human Malignant Melanoma: Five Stages Defined by Their Antigenic Phenotypes," <i>Int. J. Cancer</i> , 39:466-471 (1987)
12.	Jean et al., "Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family," <i>Molecular and Cellular Biochemistry</i> , 212:19-28 (2000)


EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ABGENIX.030C1	APPLICATION NO. 10/660,357
	APPLICANT Bar-Eli et al.	
	FILING DATE September 10, 2003	GROUP Not assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
13	Johnson, J.P., "Cell adhesion molecules in the development and progression of malignant melanoma," <i>Cancer and Metastasis Reviews</i> , 18: 345-357 (1999)
14	Johnson, J.P. et al., "Melanoma Progression-Associated Glycoprotein MUC18/MCAM Mediates Homotypic Cell Adhesion Through Interaction with a Heterophilic Ligand," <i>Int. J. Cancer</i> , 73:769-774 (1997)
15	Junghans et al., <i>Cancer Chemotherapy and Biotherapy: Principles and Practice</i> , pgs. 655-689 (2d ed., Chabner and Longo, eds., Lippincott Raven 1996)
16	Knoll et al., "Targeted Therapy of Experimental Renal Cell Carcinoma with a Novel Conjugate of Monoclonal Antibody 138H11 and Calicheamicin θ^1 ," <i>Cancer Res.</i> , 60:6089-6094 (2000)
17	Lai et al., "Two forms of 1B236/myelin-associated glycoprotein, a cell adhesion molecule for postnatal neural development, are produced by alternative splicing," <i>Proc. Natl. Acad. Sci. USA</i> , 84:4337-4341 (1987)
18	Lehmann, J.M. et al., "Discrimination Between Benign and Malignant Cells of Melanocytic Lineage by Two Novel Antigens, a Glycoprotein with a Molecular Weight of 113,000 and a Protein with a Molecular Weight of 76,000 ¹ ," <i>Cancer Res.</i> , 47:841-845 (1987)
19	Lehmann, J.M. et al. "MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neutral cell adhesion molecules of the immunoglobulin superfamily," <i>Proc. Natl. Acad. Sci. USA</i> , 86:9891-9895 (1989)
20	Liu et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids," <i>Proc. Natl. Acad. Sci. USA</i> , 93:8618-8623 (1996)
21	Luca, M. "Direct correlation between MUC18 expression and metastatic potential of human melanoma cells," <i>Melanoma Res.</i> , 3:35-41 (1993)
22	Mandler et al., "Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines," <i>J. Natl. Cancer Inst.</i> , 92(19):1573-1581 (2000)
23	Ota et al., "Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells," <i>Int. J. Clin. Oncol.</i> , 4:236-240 (1999).
24	Owens et al., "Organization of the neural cell adhesion molecule (N-CAM) gene: Alternative exon usage as the basis for different membrane-associated domains," <i>Proc. Natl. Acad. Sci. USA</i> , 84:294-298 (1987)
25	Pickl, W.F. et al., "MUC18/MCAM (CD146), An Activation Antigen of Human T Lymphocytes," <i>J. Immunol.</i> , 158:2107-2115 (1997)
26	Pourquié et al., "BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems," <i>Proc. Natl. Acad. Sci. USA</i> , 89:5261-5265 (1992)
27	Satyamoorthy, K. et al., "Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication," <i>Oncogene</i> , 20:4676-4684 (2001)
28	Schlagbauer-Wadl, et al., "Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in scid mice," <i>Int. J. Cancer</i> , 81:951-955 (1999)
29	Sers et al., Genomic organization of the melanoma-associated glycoprotein MUC18: Implications for the evolution of the immunoglobulin domains," <i>Proc. Natl. Acad. Sci. USA</i> , 90:8514-8518 (1993)
30	Sers et al., "MUC18, a Melanoma-Progression Associated Molecule, and Its Potential Role in Tumor Vascularization and Hematogenous Spread ¹ ," <i>Cancer Research</i> , 54:5689-5694 (1994)
31	Shih et al., "Expression of melanoma cell adhesion molecule in intermediate trophoblast," <i>Lab. Invest.</i> , 75(3):377-388 (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



FORM PTO-144 OCT 10 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABGENIX.030C1	APPLICATION NO. 10/660,357
		APPLICANT Bar-Eli et al.	
		FILING DATE September 10, 2003	GROUP Not assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
32	Shih et al., "Isolation and Functional Characterization of the A32 Melanoma-associated Antigen ¹ ," <i>Cancer Res.</i> , 54:2514-2520 (1994)		
33	Shih et al., "The Cell-Cell Adhesion Receptor Mel-CAM Acts As a Tumor Suppressor in Breast Carcinoma," <i>Am. J. Pathol.</i> , 151(3):745-751 (1997)		
34	Shih et al., "Melanoma Cell-Cell Interactions Are Mediated Through Heterophilic Mel-CAM/Ligand Adhesion ¹ ," <i>Cancer Res.</i> , 57:3835-3840 (1997)		
35	Shih et al., "Diagnostic and Biological Implications of Mel-CAM Expression in Mesenchymal Neoplasms," <i>Clinical Cancer Res.</i> , 2:569-575 (1996)		
36	Taira et al., "Molecular Cloning and Functional Expression of Gicerin, a Novel Cell Adhesion Molecule That Binds Neurite Outgrowth Factor," <i>Neuron</i> , 12: 861-872 (1994)		
37	Xie et al., "Expression of MCAM/MUC18 by Human Melanoma Cells Leads to Increased Tumor Growth and Metastasis ¹ ," <i>Cancer Res.</i> , 57:2295-2303 (1997)		

S:\DOCS\SRG\SRG-2103.DOC\100203\vo

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	